Various investigations have linked Pim-1 to aggressive malignant behavior and poor clinical outcome in many cancer cells, including gastric cancer [17], prostate cancer [18], esophageal squamous cell carcinoma [19], breast cancer [20], lung cancer [21], colon cancer [22], and hematological cancer [23]. Here, PIM1 is linked to prostate cancer.